Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Ant
Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.
More... |
Re: Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San
Amazing XD
|
All times are GMT -7. The time now is 12:23 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021